Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer

Shixiang Wang,Chen-Yi Wu,Ming-Ming He,Jia-Xin Yong,Yan-Xing Chen,Li-Mei Qian,Jin-Ling Zhang,Zhao-Lei Zeng,Rui-Hua Xu,Feng Wang,Qi Zhao

DOI: https://doi.org/10.1038/s41467-024-45479-6

IF: 16.6

2024-02-19

Nature Communications

Abstract:Abstract The clinical implications of extrachromosomal DNA (ecDNA) in cancer therapy remain largely elusive. Here, we present a comprehensive analysis of ecDNA amplification spectra and their association with clinical and molecular features in multiple cohorts comprising over 13,000 pan-cancer patients. Using our developed computational framework, GCAP, and validating it with multifaceted approaches, we reveal a consistent pan-cancer pattern of mutual exclusivity between ecDNA amplification and microsatellite instability (MSI). In addition, we establish the role of ecDNA amplification as a risk factor and refine genomic subtypes in a cohort from 1015 colorectal cancer patients. Importantly, our investigation incorporates data from four clinical trials focused on anti-PD-1 immunotherapy, demonstrating the pivotal role of ecDNA amplification as a biomarker for guiding checkpoint blockade immunotherapy in gastrointestinal cancer. This finding represents clinical evidence linking ecDNA amplification to the effectiveness of immunotherapeutic interventions. Overall, our study provides a proof-of-concept of identifying ecDNA amplification from cancer whole-exome sequencing (WES) data, highlighting the potential of ecDNA amplification as a valuable biomarker for facilitating personalized cancer treatment.

multidisciplinary sciences